Loomis, Sayles & Company
ALNY icon

Loomis, Sayles & Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Loomis, Sayles & Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175M Buy
580,187
+68,090
+13% +$20.5M 0.22% 50
2026
Q1 		$169M Buy
512,097
+23,200
+5% +$7.89M 0.23% 52
2025
Q4 		$194M Sell
488,897
-11,775
-2% -$5.21M 0.23% 50
2025
Q3 		$228M Buy
500,672
+13,344
+3% +$5.43M 0.27% 47
2025
Q2 		$159M Sell
487,328
-10,156
-2% -$2.81M 0.2% 57
2025
Q1 		$134M Sell
497,484
-5,561
-1% -$1.43M 0.19% 58
2024
Q4 		$118M Sell
503,045
-22,258
-4% -$5.85M 0.15% 62
2024
Q3 		$144M Sell
525,303
-43,979
-8% -$11.5M 0.19% 61
2024
Q2 		$138M Sell
569,282
-12,569
-2% -$1.98M 0.19% 60
2024
Q1 		$87M Sell
581,851
-26,877
-4% -$4.48M 0.12% 71
2023
Q4 		$117M Sell
608,728
-16,673
-3% -$2.84M 0.18% 64
2023
Q3 		$111M Sell
625,401
-19,742
-3% -$3.77M 0.19% 62
2023
Q2 		$123M Sell
645,143
-13,083
-2% -$2.59M 0.2% 60
2023
Q1 		$132M Sell
658,226
-54,330
-8% -$11.4M 0.23% 57
2022
Q4 		$169M Sell
712,556
-35,194
-5% -$7.51M 0.34% 53
2022
Q3 		$150M Sell
747,750
-80,329
-10% -$15.3M 0.3% 52
2022
Q2 		$121M Sell
828,079
-40,669
-5% -$5.77M 0.22% 57
2022
Q1 		$142M Sell
868,748
-127,689
-13% -$19.5M 0.19% 57
2021
Q4 		$169M Buy
996,437
+28,330
+3% +$5.27M 0.2% 56
2021
Q3 		$183M Buy
968,107
+22,042
+2% +$4.13M 0.22% 57
2021
Q2 		$160M Buy
+946,065
New +$139M 0.19% 61

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company's ALNY Position: Q2 2026 in Review

Loomis, Sayles & Company increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, buying an estimated $20.5M and bringing the position to 580,187 shares worth $175M. The position accounts for 0.22% of the portfolio, ranked #50.

Loomis, Sayles & Company first reported a position in ALNY in Q2 2021 and has held it in 21 quarters since. The position peaked at $228M in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Loomis, Sayles & Company held 580,187 shares of Alnylam Pharmaceuticals worth $175M as of Q2 2026.
  • Loomis, Sayles & Company bought 68,090 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $20.5M.
  • Alnylam Pharmaceuticals made up 0.22% of Loomis, Sayles & Company's portfolio in Q2 2026, its #50 holding.
  • Loomis, Sayles & Company first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Loomis, Sayles & Company's Alnylam Pharmaceuticals position peaked at $228M in Q3 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.